Evercore ISI Group analyst Duane Pfennigwerth upgrades Delta Air Lines (NYSE:DAL) from In-Line to Outperform and raises the price target from $40 to $47.
Credit Suisse analyst Judah Frommer upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underperform to Neutral and raises the price target from $6.5 to $7.